Akebia Therapeutics (AKBA) Capital Expenditures Growth (1y) (2014 - 2026)
Akebia Therapeutics (AKBA) Capital Expenditures Growth (1y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.51 Bn | 87.64 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn | 32.28% |
| 3 | Zoetis | 32.61 Bn | 30.67 Bn | 1.62 Bn | -38.20% |
| 4 | Takeda Pharmaceutical | 27.49 Bn | 23.43 Bn | 4.39 Bn | -15.72% |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | 32.98% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.26 Bn | 18.46 Bn | 1.16 Bn | -6.34% |
| 8 | Neurocrine Biosciences | 17.79 Bn | 16.47 Bn | 800.70 Mn | -86.92% |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn | -21.54% |
| 10 | Akebia Therapeutics | 341.82 Mn | 179.22 Mn | 41.25 Mn | 4,061.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4,061.11% |
| Dec 31, 2025 | 467.69% |
| Sep 30, 2025 | -84.06% |
| Jun 30, 2025 | 111.83% |
| Mar 31, 2025 | -97.06% |
| Dec 31, 2024 | 92.01% |
| Sep 30, 2024 | -94.09% |
| Jun 30, 2024 | 62.13% |
| Mar 31, 2024 | -78.20% |
| Sep 30, 2023 | -19.27% |
| Jun 30, 2023 | 53.49% |
| Mar 31, 2023 | 170.90% |
| Sep 30, 2022 | 140.64% |
| Jun 30, 2022 | -116.86% |
| Mar 31, 2022 | -191.40% |
| Sep 30, 2021 | -36.00% |
| Jun 30, 2021 | -25,245.45% |
| Mar 31, 2021 | -2,858.70% |
| Dec 31, 2020 | 67.06% |
| Sep 30, 2020 | 159.98% |